Immunotherapy, chemo, and radiation for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of immunotherapy (dostarlimab), chemotherapy (cisplatin and etoposide), and radiation to treat small cell neuroendocrine cervical cancer. The goal is to see if this approach works better and is safe for people who haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 20 and 70 years old.
- You must have a confirmed diagnosis of small cell neuroendocrine cervical cancer that has not yet been treated (stage IB2–IVB with specific spread limitations).
- You must not have received prior immunotherapy (such as anti-PD-1 or anti-PD-L1 drugs).
- You must not have had radiation to the pelvic area before.
- You must be in good general health (able to do light housework or office work – ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
Hear when a new Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.